A suite of highly specific, proprietary bacterial drug targets in staphylococcus aureus, that can be used individually or as a group to develop small molecule or peptide drug leads with powerful anti-infectives properties. More

SL is prepared by lysis of S. aureus culture with a polyvalent bacteriophage. More

A novel selective antimicrobial peptide based on human LL-37 by D-amino acid incorporation. More

Our passive immunity patent portfolio concerns the local or topical administration of monoclonal or polyclonal antibody compositions in the prevention and treatment of infectious disease. More

A class of secreted staphylococcal peptides with an extraordinary ability to recruit, activate, and subsequently lyse human neutrophils, thus eliminating the main cellular defense against S. aureus infection More

Aerosolized immunogenic compositions that may prove useful for vaccination against respiratory infections and may provide a platform for generating mucosal antibody responses against other pathogens. More

Use of Shewanella CPS conjugates as a component of an anthrax vaccine More